Latest Headlines

Latest Headlines

Roche joins Novartis' billion-dollar bet on Ophthotech's eye drug

Roche's Genentech is pairing up with Novartis to split the ex-U.S. rights to an Ophthotech eye drug, opting into an agreement that could be worth more than $1 billion.

Daiichi Sankyo and Plexxikon get FDA nod for melanoma combination

Japan's Daiichi Sankyo and its associated company Plexxikon said the U.S. Food and Drug Administration (FDA) has approved cobimetinib for the treatment of people with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with Zelboraf (vemurafenib), the company said in a statement.

Genentech, Exelixis win FDA OK to market cobimetinib combo for skin cancer

Just weeks after announcing a fresh batch of promising Phase III data, the FDA has handed Genentech and its biotech partner Exelixis an approval to market cobimetinib in combination with Zelboraf among a genetically defined group of melanoma patients.

Genentech deal continues big 2015 for in silico specialist Nimbus

This year is shaping up to be a pivotal one for Nimbus Therapeutics. Having pocketed $43 million from a clutch of big-name backers in March, the computational chemistry specialist has persuaded Roche's Genentech to license an interleukin-1 receptor-associated kinase 4 inhibitor program.

Arvinas scores $41M round, moves closer to the clinic in a landmark month

New Haven, CT-based Arvinas has hit a biotech trifecta. Over the past month the biotech grabbed recognition as a Fierce 15 company, signed up Genentech as its second marquee collaborator and now has garnered a $41.6 million B round to continue its pipeline development work.

Genentech co-signs Nimbus' computer-aided R&D with an oncology pact

Roche's Genentech is buying into Nimbus Therapeutics and its computer-driven approach to designing new drugs, partnering up on one of the company's programs in oncology and inflammation.

Genentech, Exelixis score another PhIII success for cobimetinib

Genentech has added another piece of the trial puzzle for its MEK inhibitor cobimetinib. The big Roche subsidiary's partner Exelixis announced early Tuesday that the drug combined with Zelboraf hit the mark in a Phase III study, offering a statistically significant overall survival benefit among advanced melanoma patients carrying a BRAF V600 mutation.

Genentech embraces Arvinas with $300M tie-up on protein degradation

Fresh on the heels of its inclusion in this year's Fierce 15, New Haven, CT-based Arvinas has pulled the wraps off a new partnership with Genentech that comes with a $300 million package of milestones.

Chugai and Roche get U.S. FDA priority review on alectinib

Japan's Chugai Pharmaceutical and Switzerland's Roche's and its Genentech unit received U.S. FDA acceptance for a new drug application of alectinib for ALK positive advanced non-small cell lung cancer in patients for whom crizotinib is no longer an option.

Japan's Chugai notes U.S. FDA breakthrough designation for ACE910

Japan's Chugai Pharmaceutical said the U.S. FDA has granted a breakthrough therapy designation to candidate ACE910 to prevent bleeding episodes in hemophilia A patients aged 12 and older.